Morgan Stanley lowered the firm’s price target on Procter & Gamble to $175 from $180 and keeps an Overweight rating on the shares. Fiscal Q1 upside provided a strong start to FY26, though it mainly comes out of Q2 with a tougher organic sales growth comparison in a difficult industry environment, the analyst tells investors in a post-earnings note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PG:
- Procter & Gamble: Strong Performance and Future Potential Justify Buy Rating
- Procter & Gamble: Buy Rating Affirmed Amidst Growth Potential and Strategic Reinvestment
- Procter & Gamble’s Leadership Cautious: No Trading Arrangements in Q3 2025 Raises Investor Concerns
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Procter & Gamble’s Earnings Call Highlights Strategic Growth